From original research invention to application technology improvement
we never stop pursuing innovation
Tasly Biopharma is dedicated to the research and development of innovative medicines and has established a diversified product portfolio in the areas of cardiovascular diseases, oncology and autoimmune diseases and alimentary tract and metabolism. Since its establishment, Tasly Biopharma has continued to strengthen the strategic collaboration with leading academic institutions in China and renowned biopharmaceutical companies from all over the world to enhance research and development capabilities and accelerate the transformation of innovation results. You can cooperate with Tasly Biopharma via the following ways:
In-licensing arrangements allow the introduction of candidate biologic drugs or biologic products made by the partners, and Tasly Biopharma will complete the subsequent R&D process independently.
Tasly Biopharma and its partner can establish a joint venture subsidiary company with two parties jointly investing funds and building teams for collaborative research and development and sharing various benefits after the drug is launched.
Rights to Commercialization
Tasly Biopharma invests and obtains the right to sell candidate biologic drugs/biologic products made by partners or foreign launched biologic drugs in specific countries and regions such as China.
As a fast-growing innovative biopharmaceutical company with an integrated commercial platform that covers all life cycles of biological drugs, partnerships and collaborations are critical to us, please send your business development inquiries to: